Levels of Visfatin/NAMPT in Human Milk
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPaolo Manzoni Study Group
Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.
Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities
Maternal hospitalization
Acquisition of the informed consent form signed by the patient
Refusal of the patient to participate in the study
Presence of hypogalactia or agalactia in the patient
Paolo Manzoni Study Group
Lead sponsor
Paolo Manzoni
Sponsor institution
Università degli Studi del Piemonte Orientale Amedeo Avogadro
Collaborator